Mertenil

Rosuvastatin, the active ingredient in Mertenil, is a HMG‑CoA reductase inhibitor presented as a tablet for oral use. It lowers elevated cholesterol levels and is prescribed for adults with hypercholesterolemia and for cardiovascular risk reduction. The medication works by decreasing the synthesis of low‑density lipoprotein cholesterol, helping to prevent atherosclerotic events in patients with established or high risk of heart disease.

GNH USA supplies Mertenil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Rosuvastatin is indicated for disorders of lipid metabolism and for cardiovascular disease prevention. - Hypercholesterolemia: lowers LDL‑cholesterol and total cholesterol to target levels. - Primary prevention of cardiovascular disease: reduces risk of myocardial infarction, stroke and related events in high‑risk patients without prior events. - Secondary prevention of cardiovascular disease: decreases recurrence of cardiovascular events in patients with established coronary artery disease or prior stroke. - Mixed dyslipidemia: improves the overall lipid profile by reducing triglycerides and increasing HDL‑cholesterol.

Rosuvastatin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache - Muscle pain (myalgia) - Nausea - Elevated liver enzymes

Serious or Rare Side Effects: - Rhabdomyolysis with possible renal failure - Severe liver injury - Allergic reactions including anaphylaxis

When prescribing rosuvastatin, several safety considerations are recommended. - Assess liver function: obtain baseline hepatic enzymes before initiating therapy. - Monitor lipid levels: check fasting lipid profile periodically to evaluate efficacy. - Evaluate renal function: adjust use in patients with severe renal impairment. - Avoid use in pregnancy: teratogenic risk; discontinue before conception. - Caution in patients with a history of muscle disorders: monitor for myopathy symptoms. - Store at room temperature: keep below 25 °C, protect from moisture and light in original packaging.

Rosuvastatin interacts with several medicines that may alter its concentration or increase toxicity.

Major Interactions (Avoid): - Concomitant use with cyclosporine: may markedly increase rosuvastatin plasma concentrations. - Co‑administration with strong CYP2C9 inhibitors (e.g., fluconazole): raises risk of myopathy. - Use with gemfibrozil or other fibrates: heightened chance of rhabdomyolysis.

Moderate Interactions (Monitor Closely): - Co‑administration with warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Use with antacids containing aluminum or magnesium: can reduce rosuvastatin absorption; separate dosing by at least 2 hours. - Concurrent use with niacin: may increase risk of liver enzyme elevations.